美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · NBIX近 30 天 7 則 · 第 1 / 1 頁
- Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
- Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
- Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
- Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
- Neurocrine Biosciences (NBIX) Stock Looks Fairly Priced As 64% Gain Holds
- Neurocrine Biosciences (NBIX) Cleared For Phase 2 Alzheimer’s Cognition Study
- Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
- Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
- Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
- NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
- Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
- XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
- Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
- Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。